Medical Database

The HIV Co-Receptor Tropism (Trofile) Assay is a molecular test used to determine which cellular co-receptor, CCR5 or CXCR4, HIV-1 predominantly uses to enter host cells. This information can guide the use of CCR5 antagonist antiretroviral therapies, such as maraviroc, which are effective only against CCR5-tropic virus. The assay analyzes viral envelope sequences or functional viral entry to characterize HIV-1 tropism and may identify CCR5-tropic, CXCR4-tropic, or dual/mixed-tropic populations. Testing is generally performed using plasma from individuals with detectable HIV-1 RNA. Results can help clinicians evaluate whether a CCR5-targeting regimen is appropriate, particularly in treatment-experienced patients. Interpretation should consider viral load, treatment history, assay sensitivity, and current antiretroviral therapy guidelines.

Prostate Cancer Antigen 3 (PCA3) is prostate-specific, that is markedly overexpressed in prostate cancer cells compared with benign prostate tissue. PCA3 testing is typically performed on urine collected after a digital re**al examination, which releases prostate cells into the urinary tract. The assay measures PCA3 RNA and commonly reports a PCA3 score based on the ratio of PCA3 to prostate-specific antigen (PSA) RNA. Unlike serum PSA, PCA3 is less influenced by benign prostatic hyperplasia and prostatitis. PCA3 testing may help assess the likelihood of prostate cancer, particularly in men with an elevated or persistently abnormal PSA level and a previous negative biopsy. Results should be interpreted alongside clinical findings, PSA levels, imaging, and other risk factors.

Fibroblast Growth Factor 23 (FGF23) is a hormone primarily produced by bone cells, particularly osteocytes and osteoblasts, and plays a central role in regulating phosphate and vitamin D metabolism. FGF23 acts mainly on the kidneys to reduce phosphate reabsorption by decreasing sodium-phosphate cotransporter expression, thereby promoting urinary phosphate excretion. It also suppresses the production of 1,25-dihydroxyvitamin D (calcitriol), reducing intestinal phosphate absorption. FGF23 activity requires the co-receptor α-Klotho. Measurement of circulating FGF23 may assist in evaluating disorders of phosphate homeostasis, including hereditary hypophosphatemic disorders, tumor-induced osteomalacia, and chronic kidney disease.

G6PC (Glucose-6-phosphatase, Catalytic Subunit) gene mutation analysis is a molecular genetic test used to identify pathogenic variants associated with Glycogen Storage Disease Type 1a (GSD Ia), also known as von Gierke disease. GSD Ia is an autosomal recessive metabolic disorder caused by impaired glucose-6-phosphatase activity, resulting in defective conversion of glucose-6-phosphate to free glucose. Affected individuals may develop severe fasting hypoglycemia, hepatomegaly, lactic acidosis, hyperuricemia, and hyperlipidemia. Molecular testing typically evaluates the G6PC gene for sequence variants and may help confirm a clinical diagnosis, distinguish GSD Ia from other glycogen storage disorders, and support family or carrier testing.

Plasma phosphorylated tau 217 (p-tau217) is a blood-based biomarker associated with Alzheimer’s disease (AD) pathology. Tau hyperphosphorylation contributes to the formation of neurofibrillary tangles, a characteristic feature of AD. Elevated plasma p-tau217 levels are strongly associated with amyloid-β and tau pathology identified by cerebrospinal fluid (CSF) analysis and positron emission tomography (PET). Levels increase progressively in amyloid-positive individuals and correlate with advancing tau pathology, cognitive decline, and disease progression. Plasma p-tau217 may also help distinguish AD from other neurodegenerative disorders, including frontotemporal dementia, progressive supranuclear palsy, and Parkinson’s disease.

Chitotriosidase is a chitin-degrading enzyme produced predominantly by activated macrophages and is measured in serum as a biomarker of macrophage activation and lysosomal storage disorders. Serum chitotriosidase testing is particularly useful in the evaluation and monitoring of Gaucher disease, in which levels may correlate with disease burden and treatment response. Markedly elevated activity can also occur in other conditions associated with macrophage activation, including certain lysosomal storage disorders, infections, and inflammatory diseases. Testing may support diagnosis when interpreted alongside clinical findings, enzyme studies, and genetic analysis. Serial measurements can help assess response to enzyme replacement or substrate reduction therapy.

Chymotrypsin is a proteolytic digestive enzyme produced by the pancreas and released into the small intestine, where it helps break down dietary proteins. Because chymotrypsin remains relatively stable during intestinal transit, its concentration in stool can provide an indirect measure of pancreatic enzyme secretion. Reduced f***l chymotrypsin levels may indicate pancreatic exocrine insufficiency, which can occur in chronic pancreatitis, cystic fibrosis, pancreatic tumors, or after pancreatic surgery. The test may be useful in evaluating symptoms such as chronic diarrhea, steatorrhea, abdominal discomfort, weight loss, and malabsorption. Results should be interpreted alongside clinical findings and other pancreatic function tests, particularly f***l elastase.

HBB (hemoglobin subunit beta) gene mutation analysis is a molecular genetic test used to identify pathogenic variants in the HBB gene, which encodes the beta-globin component of adult hemoglobin (HbA). Mutations in HBB can alter hemoglobin production or structure and are associated with inherited hemoglobin disorders, including sickle cell disease, beta-thalassemia, and other hemoglobinopathies. Testing may detect specific known variants or sequence the HBB gene to identify previously unrecognized mutations. Results can help confirm a suspected hemoglobinopathy, clarify disease subtype, and support carrier and family testing. HBB mutation analysis may be particularly useful when hemoglobin electrophoresis or other hematologic findings suggest an inherited disorder.

Catechol-O-methyltransferase (COMT) genotyping is a molecular test used to identify genetic variants in the COMT gene, which encodes an enzyme involved in the metabolism of catecholamines, including dopamine, epinephrine, and norepinephrine. One commonly evaluated variant is Val158Met (rs4680), which can alter COMT enzyme activity and influence catecholamine metabolism. Genotyping may help investigate interindividual differences in neurotransmitter metabolism and has been studied in relation to pain sensitivity, psychiatric conditions, cognition, and response to certain medications. The test is typically performed using DNA extracted from whole blood or buccal specimens, followed by PCR-based or sequencing methods.

MI-2 autoantibodies are myositis-specific antibodies directed against the Mi-2 protein, which plays a role in chromatin remodeling and gene regulation. They are strongly associated with dermatomyositis, particularly classic dermatomyositis with prominent skin manifestations. Patients may present with proximal muscle weakness, elevated muscle enzymes, heliotrope rash, and Gottron papules. Although anti-Mi-2 antibodies are detected in a relatively small proportion of patients with idiopathic inflammatory myopathies, their presence provides valuable support for dermatomyositis diagnosis and classification. MI-2 antibody testing is commonly included in myositis antibody panels and may help characterize disease phenotype. Anti-Mi-2-positive patients generally have a favorable response to treatment and prognosis.